Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 16/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 9/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23118016 | 0.99 | IDO1 (0.55) | IDO1S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL20863852 | 0.86 | S1PR1 (0.47) | S1PR1S1PR3S1PR4S1PR5ADORA3 | |
| SCHEMBL22504238 | 0.82 | S1PR1 (0.47) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL27906385 | 0.82 | S1PR1 (0.52) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL19119505 | 0.82 | S1PR1 (0.49) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL2235318 | 0.82 | S1PR1 (0.43) | S1PR1S1PR3S1PR4S1PR5ADORA3 | |
| SCHEMBL24075682 | 0.81 | NUDT1 (0.58) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL20863953 | 0.81 | S1PR1 (0.42) | S1PR1S1PR3S1PR4S1PR5ADORA3 | |
| SCHEMBL22504242 | 0.81 | S1PR1 (0.42) | S1PR1S1PR3S1PR4S1PR5ADORA3 | |
| SCHEMBL18671230 | 0.81 | S1PR1 (0.45) | S1PR1S1PR3S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112745244-B | Intermediate of simotimod and synthesis method thereof | 苏州科伦药物研究有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20230212115-A1 | METHODS FOR THE PREPARATION OF SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS AND SOLID FORME THEREOF | CIPLA LIMITED (IN) | 2023-07-06 | — | — | US | disclosed |
| US-20230212115-A1 | METHODS FOR THE PREPARATION OF SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS AND SOLID FORME THEREOF | CIPLA LIMITED (IN) | 2023-07-06 | — | — | US | disclosed |
| US-20230212115-A1 | METHODS FOR THE PREPARATION OF SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS AND SOLID FORME THEREOF | CIPLA LIMITED (IN) | 2023-07-06 | — | — | US | disclosed |
| US-11673860-B2 | Crystalline siponimod fumaric acid and polymorphs thereof | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2023-06-13 | — | — | US | disclosed |
| US-11673860-B2 | Crystalline siponimod fumaric acid and polymorphs thereof | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2023-06-13 | — | — | US | disclosed |
| US-11673860-B2 | Crystalline siponimod fumaric acid and polymorphs thereof | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2023-06-13 | — | — | US | disclosed |
| US-20220204446-A1 | PROCESS FOR MAKING SIPONIMOD AND INTERMEDIATE THEREOF | SYNTHON B.V. (NL) | 2022-06-30 | — | — | US | disclosed |
| WO-2021240547-A2 | METHODS FOR THE PREPARATION OF SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS AND SOLID FORMS THEREOF | CIPLA LIMITED (IN) | 2021-12-02 | — | — | WO | disclosed |
| CN-112745244-A | Intermediate of siponimod and synthesis method thereof | 苏州科伦药物研究有限公司 | 2021-05-04 | — | — | CN | disclosed |
| EP-1633336-A4 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2008-10-29 | — | — | EP | disclosed |
| EP-1718604-A4 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2008-02-13 | — | — | EP | disclosed |
| US-20070167410-A1 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2007-07-19 | — | — | US | disclosed |
| CN-1922135-A | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2007-02-28 | — | — | CN | disclosed |
| EP-1718604-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM, LLC (BM) | 2006-11-08 | — | — | EP | disclosed |
| CN-1791395-A | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2006-06-21 | — | — | CN | disclosed |
| EP-1633336-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005082841-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2005-09-09 | — | — | WO | disclosed |
| US-20050014728-A1 | Immunosuppressant compounds and compositions | IRM LLC | 2005-01-20 | — | — | US | disclosed |
| WO-2004103306-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014728-A1 | Immunosuppressant compounds and compositions | ICOS, EDNRA, NFATC1 | IDO1 28/4885S1PR1 133/4885S1PR3 142/4885 |
| US-20230212115-A1 | METHODS FOR THE PREPARATION OF SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS AND SOLID FORME THEREOF | S1PR1, S1PR2, S1PR3 | IDO1 2940/4885S1PR1 1/4885S1PR3 3/4885 |
| US-11673860-B2 | Crystalline siponimod fumaric acid and polymorphs thereof | FGF23, BRAF, FGFR1 | IDO1 4536/4885S1PR1 36/4885S1PR3 53/4885 |
| US-20220204446-A1 | PROCESS FOR MAKING SIPONIMOD AND INTERMEDIATE THEREOF | S1PR5, SPHK2, S1PR2 | IDO1 329/4885S1PR1 4/4885S1PR3 7/4885 |
| US-20070167410-A1 | Immunosuppressant compounds and compositions | ICOS, EDNRA, NFATC1 | IDO1 27/4885S1PR1 141/4885S1PR3 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.